White Paper
Local Representation: What Clinical Trial Sponsors Need to Know
In this white paper, best practices are described as well as required Sponsor/Local Representative agreement areas. It is important that major…
All Results
White Paper
Case Study
PRA Leads Novel Multiple Myeloma Drug Development
PRA Health Sciences supported 2 multiple myeloma clinical trials, a Phase III and a “rollover,” for a large biotech client. This management contract…
Webcast
Practical Implementation of Signal Detection in Iterative Benefit Risk Evaluation
This webcast with PRA Health Sciences' Jacinta Aniagolu-Johnson (Senior Director, Safety and Risk Management) explores how a well defined signal…
White Paper
Sponsor and CRO Pharmacovigilance Alliances
Outsourcing pharmacovigilance activities is a standard business practice in a continuously expanding market segment. In the past, outsourced safety…
Resource
PRA Health Sciences To Report Fourth Quarter 2014 Earnings
PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and year end 2014 results after the market closes on Wednesday, February 18,…
Page
Pharmacovigilance & Patient Safety
Clinical trial participants help us speed breakthroughs in modern drug development. Our job is to protect them.